Biosimilars

Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine

Shots: The company has completed the patient dosing in the PK and PD study of bios...

Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Marketing Authorization for Retinal Diseases

Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Marketing Authorization for Retinal Diseases

Shots: The EC has granted the marketing authorization for Ranivisio, a biosimilar...

Lupin Entered into an Exclusive License Agreement with I’rom for Denosumab Biosimilar in Japan

Lupin Entered into an Exclusive License Agreement with I’rom for Denosumab Biosimilar in Japan

Shots: Lupin will receive multiple milestones fees payments & I’rom will...

Image